Aura Biosciences, Inc. AURA
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +28.07%
- 1 year
- +29.26%
5D +0.47 (+7.08%)
- Market cap
- 726.44M
- EPS (ttm)
- -1.55
- Shares out
- 49.95M
- Forward P/E
- -4.05
- YTD return
- +28.07%
- 1-year return
- +29.26%
- 50-day average
- 9.67
- 200-day average
- 8.40
- Enterprise value
- 254.31M
- Volume
- 495.31K
- Avg volume
- 844.99K
- Open
- 7.11
- Previous close
- 7.14
- Day's range
- 6.83 – 7.24
- 52-week range
- 4.73 – 9.54
- Beta
- 0.33
- Analysts
- Strong Buy
- Price target
- 21.83 (+212.8%)
Key statistics
- Price / book
- 2.35
- Free cash flow
- -47.35M
- Total cash
- 174.38M
- Total debt
- 19.08M
- Return on equity
- -50.99%
- Short % of float
- 2.80%
Fundamental scorecard
5 of 25 checks passed on AURA’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.44 | -0.42 | +0.02 | +4.55% |
| Aug 8, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.45 | -0.41 | +0.04 | +8.89% |
| May 9, 2024 | Mar 1, 2024 | -0.51 | -0.40 | +0.11 | +21.57% |
| May 9, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 18, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Oct 18, 2024 | BTIG | main | Buy | Buy |
| Oct 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 13, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Sep 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aurabiosciences.com
News
OXB Confirms Manufacturing And Supply Partnership With Aura Biosciences For Late-Stage Development And Manufacturing Activities Of Belzupacap Sarotalocan
OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
Here's Why You Should Add AURA Stock to Your Portfolio Now
Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade Aura Biosciences Q3 EPS $(0.29) Beats $(0.37) Estimate
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
Your note
Sign in to keep a note on AURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE LOS PINOS ELISABET | Chief Executive Officer | Sale | Oct 28, 2024 | 452,059 |
| ELAZZOUZI AMY | Officer | Sale | Oct 28, 2024 | 39,443 |
| FEDER JULIE B | Chief Financial Officer | Sale | Oct 17, 2024 | 134,276 |
| HOPKINS JANET JILL | Officer | Sale | Nov 17, 2024 | 151,693 |
| JOHNSON DAVID MICHAEL | Director | Stock Award(Grant) | Jun 19, 2024 | 435,839 |
| KILROY CONOR | General Counsel | Stock Award(Grant) | Apr 1, 2024 | 96,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Matrix Capital Management | 13.86% | 6,922,870 | 56.98M | Sep 29, 2024 |
| Eventide Asset Management LLC | 11.62% | 5,802,682 | 47.76M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 9.77% | 4,881,125 | 40.17M | Sep 29, 2024 |
| Blackrock Inc. | 6.33% | 3,160,414 | 26.01M | Sep 29, 2024 |
| Medicxi Ventures Management (Jersey) Ltd | 6.09% | 3,039,892 | 25.02M | Sep 29, 2024 |
| Vanguard Group Inc | 3.61% | 1,805,434 | 14.86M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 11.62% | 5,802,682 | 47.76M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.27% | 1,133,224 | 9.33M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.70% | 848,999 | 6.99M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.27% | 633,967 | 5.22M | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.14% | 568,471 | 4.68M | Jul 30, 2024 |
| Fidelity Small Cap Index Fund | 0.95% | 473,964 | 3.90M | Aug 30, 2024 |
